What is Imbio?
Imbio operates at the intersection of advanced machine learning and clinical diagnostics, specializing in AI-driven medical imaging analysis for lung and cardiothoracic conditions. The company provides a robust suite of tools, including algorithms for pulmonary hypertension, lung density, and coronary calcification, which are designed to enhance the precision of personalized medicine. By offering secure, scalable, and interoperable deployment options, Imbio enables physicians and health systems to optimize diagnostic accuracy. Furthermore, the firm maintains strategic partnerships with pharmaceutical and medical device manufacturers, facilitating the development of disease-specific imaging solutions that support the entire spectrum of patient care and therapeutic management.
How much funding has Imbio raised?
Imbio has raised a total of $2.7M across 3 funding rounds:
Private Equity
$1.1M
Series A
$1.5M
Debt
$150K
Private Equity (2015): $1.1M, investors not publicly disclosed
Series A (2017): $1.5M led by Invenshure
Debt (2020): $150K supported by PPP
Key Investors in Imbio
Invenshure
Invenshure is a venture firm focused on transforming institutional intellectual property into commercial ventures, utilizing in-house scientific expertise to nurture early-stage innovation.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed investor participating in the funding round to support long-term strategic development and market expansion.
What's next for Imbio?
With the recent infusion of capital, Imbio is poised to scale its enterprise-level operations and expand its global footprint. The company's strategic roadmap likely involves deepening its integration with existing hospital information systems and broadening its portfolio of FDA-cleared algorithms. As the demand for automated, high-fidelity diagnostic tools continues to rise, Imbio is expected to leverage its current financial backing to pursue further clinical validation studies and explore new therapeutic areas. This growth phase will be critical in cementing the company's status as a leader in the digital health landscape, particularly as it continues to refine its collaborative models with major industry stakeholders to drive innovation in patient-centric diagnostic processes.
See full Imbio company page
